InflammamiR-146a and -155 Plasma Levels are Associated with Clinical Efficacy of Risankizumab Treatment in Psoriatic Patients: Pilot Study.

Diotallevi FedericoGiulia MatacchioneGiovanni Marco d'AgostinoHelena GioacchiniAnna CampanatiJacopo SabbatinelliFabiola OlivieriAnnamaria Offidani

Published in: Dermatology and therapy (2023)

Our results reinforce the notion that specific circulating miRNAs could have clinical relevance as diagnostic/prognostic biomarkers of psoriatic disease and suggest the potential relevance of these miRNAs as biomarkers of treatment response.

Keyphrases

rheumatoid arthritis
end stage renal disease
ejection fraction
ankylosing spondylitis
newly diagnosed
disease activity
chronic kidney disease
systemic lupus erythematosus
climate change
risk assessment